Navigation Links
Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
Date:10/28/2008

- Laureate To Manufacture Tolera's Monoclonal Antibody Product Candidate -

PRINCETON, N.J., Oct. 28 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has entered into a cGMP contract manufacturing agreement with Tolera Therapeutics, Inc., a biotechnology company that develops and offers targeted therapies and safer solutions for immune modulation and related medical needs. According to the agreement, Laureate will produce Tolera's TOL101 monoclonal antibody under cGMP conditions to be used in clinical trials. Terms of the manufacturing agreement were not disclosed.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )

"We are pleased to work closely with Tolera to accelerate their antibody therapeutics program to clinic," said Robert J. Broeze, Ph. D., President & Chief Executive Officer of Laureate. "We are committed to providing Tolera with superior services to help them achieve their manufacturing objectives."

"We are excited to work with Laureate, a company with demonstrated expertise in biopharmaceutical manufacturing. Their capabilities in both clinical and commercial-grade materials can support our aggressive development and commercial plans," said John J. Puisis, President and Chief Executive Officer of Tolera. "We look forward to our partnership with Laureate in utilizing their specialized experience in the manufacture of monoclonal antibodies."

About Laureate Pharma, Inc.

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or info@laureatepharma.com or visit http://www.laureatepharma.com.

About Tolera Therapeutics, Inc.

Tolera Therapeutics is a biotechnology company developing novel therapies for patients and doctors providing more targeted and safer clinical solutions for immune modulation and related therapies. The company recently closed its Series A round and intends to commercialize its lead therapeutic agent TOL101 (T-cell modulation) for acute rejection in kidney transplantation, followed by additional development and commercialization in autoimmune and oncology applications. For further information, visit http://www.tolera.com.


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Laureate Announces Manufacturing Agreement with Tolerx
2. Laureate Pharma to Add More Manufacturing Capacity
3. ARUP Laboratories ARUP Consult(R) Recognized as a Computerworld Honors Program Laureate
4. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
5. Laureate Pharma Reports Record Growth for 2007
6. Laureate Pharma Appoints Gary Swan as Vice President of Operations
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. American Scientists Named as Laureates of the 2008 (24th) Japan Prize
10. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
11. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... ... sector professionals, has announced the addition of 5 new courses to its prospectus. ... Compliance with Regulation 21 CFR Part 11 on Electronic Records and Electronic Signatures ...
(Date:9/21/2017)... ... September 21, 2017 , ... Lajollacooks4u welcomed the San Diego chapter of Les ... society of professional women with high achievement in the fields of food, fine beverage ... , Twelve members began with an olive oil tasting to whet their palettes and ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... collaboration with Koch Agronomic Services (Koch) to feature new innovations aimed at helping ... broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. Check ...
(Date:9/20/2017)... ... ... Diversity focused business accelerator, The Refinery , announced today they are hosting ... technology-driven, women-led startups in Boston, MA, New Haven/Hamden, CT, and Newark, NJ. Fueling ... that week – in Boston, it will be part of the City of Boston's ...
Breaking Biology Technology:
(Date:4/13/2017)... MONICA, Calif. , April 13, 2017 ... New York will feature emerging and evolving ... Summits. Both Innovation Summits will run alongside the expo ... of speaker sessions, panels and demonstrations focused on trending ... coast,s largest advanced design and manufacturing event will take ...
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
Breaking Biology News(10 mins):